摘要
直接抗病毒药物(DAAs)治疗慢性丙型肝炎病毒感染获得了较高的持续病毒学应答率。但耐药相关突变(RAVs)在其治疗失败中有着重要作用,引起越来越多的临床关注。现从DAAs耐药相关突变的定义,RAVs与基因型的关系,已知耐药突变及其流行率,RAVs对于初治及经治患者的影响,以及耐药检测的临床作用方面阐述RAVs的临床意义,以期对优化临床DAAs治疗方案提供借鉴,获得更高的持续病毒学应答率。
Direct-acting antiviral agents (DAAs) achieve a high sustained virologic response rate in the treatment of chronic hepatitis C virus infection. However, drug resistance-associated mutations play an important role in treatment failure and have attracted more and more attention. This article elaborates on the clinical significance of drug resistance-associated mutations from the aspects of their definition, association with genotype, known drug resistance-associated mutations and their prevalence rates, the impact of drug resistance-associated mutations on treatment naive and treatment-experienced patients, and the role of clinical detection, in order to provide a reference for clinical regimens with DAAs and help to achieve higher sustained virologic response rates.
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2017年第3期170-174,共5页
Chinese Journal of Hepatology
关键词
肝炎
丙型
直接抗病毒药物
耐药
Hepatitis C
Directly acting antivirals
Resistance associated substitution